Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
July 20 2021 - 8:17AM
Business Wire
Expanded Board to build on company’s recent successes in
oncology diagnostics and COVID-19 testing
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, has appointed Linda
Rubinstein and Antonino Morales to its Board of Directors,
effective immediately. The company also named Director Samuel D.
Riccitelli as Chairman of the Board, succeeding long-time Chair
David Hale and interim Chair M. Faye Wilson, both of whom remain
Directors.
Rubinstein and Morales each brings extensive financial expertise
and leadership experience to the Board, supporting Biocept’s focus
on strategic growth and the advancement of its oncology diagnostics
franchise. With these two additions, Biocept’s Board will increase
from seven Directors to nine.
“We are proud to expand and strengthen our Board of Directors
with these new appointments, which we believe will support recent
business momentum and guide our long-term success,” said Michael
Nall, President and CEO of Biocept. “Sam will provide strong
governance, leadership and insight as Chairman, while Linda and
Antonino bring fresh perspectives, diverse backgrounds and a wealth
of valuable experience to the Board. We are especially grateful to
David Hale for serving as our previous Chairman and to Faye Wilson
for stepping up as interim Chair.”
Rubinstein has over 30 years of financial and capital markets
experience in life sciences and investment banking. As CFO of
public and private companies, she has contributed to strategy and
operations, executed financial transactions, and delivered
corporate and investor positioning. Since 2010 she has been a
partner at FLG Partners, where she provides financial and strategic
consulting services to life science and other companies such as
Apexigen, ArmaGen, Five Prime, Kezar Life Sciences, Ingenuity
Systems, iPierian and True North. Previously, she was a Principal
at RDJ Advisors. Rubinstein also served as Vice President and CFO
at Solexa, a biotech company with a leading DNA sequencing platform
for genetic analysis, where in 2006 she helped negotiate the sale
to Illumina, a global leader in genomics.
Morales is a CPA and brings more than 30 years of broad
international executive leadership experience in financial
consulting, business development, operations, regulatory
compliance, and risk management. He has worked with leading
organizations such as Citibank, Bank of America, Arthur Anderson
and Mazda North America, as well as with entrepreneurial start-ups.
Most recently, Morales was president and CEO of Apoyo Financiero,
Inc., a California based Community Development Financial
Institution where he led a major digital transformation of the
business model resulting in increased sales and profit growth.
Riccitelli was appointed to the Biocept Board of Directors in
October 2020. He has more than 35 years of experience in the
healthcare industry and currently serves as an independent
consultant to healthcare companies and as a Director of
OrthoPediatrics Corp.
“I am honored to have the opportunity to serve as Biocept’s
Chairman of the Board,” Riccitelli said. “The company is making
remarkable strides in oncology diagnostics, especially in
neuro-oncology with the recent launch of the CNSide™ cerebrospinal
fluid assay to aid in the identification and management of brain
metastases. This esteemed group of Directors, now with the addition
of Linda and Antonino, is committed to furthering Biocept’s
strategic growth initiatives and advancing its molecular diagnostic
services, with the ultimate goal of helping to improve clinical
outcomes for patients with cancer.”
About Biocept Biocept, Inc. develops and commercializes
molecular diagnostic assays that provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with a variety of cancers. In addition to its broad
portfolio of blood-based liquid biopsy assays, Biocept has
developed the CNSide™ cerebrospinal fluid assay that detects cancer
that has metastasized to the central nervous system. Biocept’s
patented Target Selector™ technology captures and quantitatively
analyzes CSF tumor cells for tumor-associated molecular markers,
using technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the ability of Biocept’s molecular diagnostic
assays to provide physicians with clinically actionable information
for treating and monitoring patients diagnosed with a variety of
cancers, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risks and uncertainties, including the risk
that our products and services may not perform as expected. These
and other risks are described in greater detail under the "Risk
Factors" heading of our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2021. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005373/en/
Biocept Contacts Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301 Investors: Jody Cain, LHA
Investor Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024